^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    XTX202

    i
    Associations
    News

    Trials

    Company:
    Xilio Therap
    Drug class:
    IL-2βγR agonist
    Related drugs:
    Associations
    News

    Trials

    Apply
    XTX202 in Patients With Advanced Solid Tumors (XTX202-01) (NCT05052268)
    Phase 1/2
    Xilio Development, Inc.
    Active, not recruiting
    Last update posted :
    04/05/2024
    Initiation :
    01/18/2022
    Primary completion :
    02/08/2026
    Completion :
    02/08/2026
    BRAF
    |
    BRAF mutation • BRAF V600
    |
    XTX202